SCHEMBL16740797

SCHEMBL16740797

COc1ccc(Nc2nc(N)nc(-n3c(C4CC4)nc4c(F)cccc43)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 1/20 0.47
SLC29A2 Q14542 1/20 0.46
SLC29A1 Q99808 1/20 0.46
IDH1 O75874 1/20 0.45
MAPK8 P45983 4/20 0.43
MAPK9 P45984 4/20 0.43
MAPK10 P53779 4/20 0.43
MAPK14 Q16539 2/20 0.43
MAPT P10636 4/20 0.41
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
JAK2 O60674 1/20 0.41
POLB P06746 1/20 0.41
PKM P14618 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740853 0.90 HTT (0.43) BMI1MAPTALDH1A1KDM4ENPC1
SCHEMBL16748502 0.89 BMI1 (0.49) BMI1SLC29A2SLC29A1IDH1MAPK8
SCHEMBL16748447 0.88 BMI1 (0.35) BMI1SLC29A2SLC29A1IDH1MAPT
SCHEMBL16748596 0.88 MAPK1 (0.38) BMI1MAPTALDH1A1KDM4ENPC1
SCHEMBL16748499 0.86 BMI1 (0.47) BMI1MAPT
SCHEMBL16740743 0.85 SLC29A2 (0.47) BMI1SLC29A2SLC29A1IDH1MAPK8
SCHEMBL16740769 0.85 BMI1 (0.64) BMI1MAPTALDH1A1KDM4ENPC1
SCHEMBL16748432 0.83 SLC29A2 (0.47) BMI1SLC29A2SLC29A1IDH1MAPT
SCHEMBL16740819 0.81 BMI1 (0.38) BMI1IDH1ALDH1A1
SCHEMBL16748422 0.81 BMI1 (0.49) BMI1SLC29A2SLC29A1MAPK8MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885SLC29A2 3585/4885SLC29A1 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.